{"id":60996,"date":"2025-03-27T19:02:50","date_gmt":"2025-03-27T18:02:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/"},"modified":"2025-03-27T19:02:50","modified_gmt":"2025-03-27T18:02:50","slug":"cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/","title":{"rendered":"Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25"},"content":{"rendered":"
\n

\nCleerly to Present Late-Breaking Findings and Participate in Key ACC.25 Sessions<\/i>\n<\/p>\n

DENVER–(BUSINESS WIRE)–#AI<\/a>—Cleerly<\/a>, the leader in cardiovascular AI imaging, announces its participation in the American College of Cardiology Annual Scientific Session + Expo (ACC.25)<\/b><\/a> from March 29-31, 2025<\/b>, at the McCormick Place Convention Center in Chicago, Illinois. Cleerly will share its late-breaking findings on Artificial Intelligence-based Quantitative Computed Tomography\u2019s (AI-QCT\u2019s) role in identifying risks of future major adverse cardiovascular events (MACE) in women. Onsite, Cleerly will demonstrate the company\u2019s AI-enabled coronary computed tomography angiography (CCTA) solution to help guide personalized prognosis, diagnosis, and treatment of coronary artery disease (CAD).\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nLate-Breaking Clinical Trial Presentation<\/b>\n<\/p>\n

\nIn the session \u201cClinical and Investigative Horizons\u201d on March 31st at 9:00 AM<\/b>, Dr. Gudrun Feuchtner will present late-breaking clinical research titled \u201cArtificial Intelligence-based Quantitative Computed Tomography (AI-QCT) Coronary Plaque Features Predict Risk More Pronounced in Females: The International Multicentric Registry CONFIRM2,\u201d on behalf of the CONFIRM2 investigators. This groundbreaking research will shine a light on the potential role of Cleerly\u2019s AI-QCT for measuring disease in women, in whom coronary artery disease is often underdiagnosed and undertreated. CONFIRM2 is one of the few studies in which about 50% of the participants are female<\/b>. With a diverse trial population of 3,500 participants from sites across 11 countries, this study highlights the generalized applicability of the results in addressing cardiovascular health disparities.\n<\/p>\n

\nSessions and Abstracts<\/b>\n<\/p>\n

\nCleerly\u2019s founder and CEO, Dr. James Min, will be featured on the Health Equity Panel on March 30th from 2:30 – 3:30 PM<\/b>. This session, titled \u201cChampioning Communities of Health: A Cross-Industry Panel Discussion on Community Education, Cardiovascular Disease Prevention, and Screening Programs,\u201d will address critical issues surrounding health equity and the importance of community engagement in cardiovascular health.\n<\/p>\n

\nCleerly will also participate in a Lounge & Learn Session titled \u201cIncreasing Female Physician Leadership in Clinical Trials\u201d on March 30th from 1:00 – 1:30 PM<\/b> in the Education Zone, Theater 1 of the Lounge and Learn Pavilion. Additionally, Cleerly will present six additional abstracts<\/b> throughout the conference, showcasing advancements in heart health technology and research.\n<\/p>\n

\nVisit Cleerly at Booth #16033<\/b>\n<\/p>\n

\nStop by and learn more about Cleerly at booth #16033, <\/b>where a coffee bar with barista service <\/b>will be available for all visitors. The Cleerly team will be available to demonstrate the technology, including its COMPARE feature, which enables clinicians to track the progression of plaque over time.\n<\/p>\n

\nAttendees can also stop by Cleerly\u2019s \u201cMeet Cleerly Leadership\u201d<\/b> event on Sunday, March 30th from 12:30 to 1:30 PM<\/b>, for an opportunity to talk with Cleerly leadership and enjoy a complimentary lunch-style buffet. To see a full schedule of Cleerly presentations or schedule a meeting with Cleerly leadership, please visit this link<\/a>.\n<\/p>\n

\nAbout Cleerly<\/b>\n<\/p>\n

\nCleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly\u2019s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCleerly Media Contact<\/b>
Christy Sievert
\n
press@cleerlyhealth.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Cleerly to Present Late-Breaking Findings and Participate in Key ACC.25 Sessions DENVER–(BUSINESS WIRE)–#AI—Cleerly, the leader in cardiovascular AI imaging, announces its participation in the American College of Cardiology Annual Scientific Session + Expo (ACC.25) from March 29-31, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Cleerly will share its late-breaking findings on Artificial … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-60996","format-standard","category-industry"],"yoast_head":"\nCleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Cleerly to Present Late-Breaking Findings and Participate in Key ACC.25 Sessions DENVER–(BUSINESS WIRE)–#AI—Cleerly, the leader in cardiovascular AI imaging, announces its participation in the American College of Cardiology Annual Scientific Session + Expo (ACC.25) from March 29-31, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Cleerly will share its late-breaking findings on Artificial ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-27T18:02:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250327234965\/en\/2421585\/22\/ACC-General-Event-Release-_2_V1_2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25\",\"datePublished\":\"2025-03-27T18:02:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\\\/\"},\"wordCount\":553,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250327234965\\\/en\\\/2421585\\\/22\\\/ACC-General-Event-Release-_2_V1_2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\\\/\",\"name\":\"Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250327234965\\\/en\\\/2421585\\\/22\\\/ACC-General-Event-Release-_2_V1_2.jpg\",\"datePublished\":\"2025-03-27T18:02:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250327234965\\\/en\\\/2421585\\\/22\\\/ACC-General-Event-Release-_2_V1_2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250327234965\\\/en\\\/2421585\\\/22\\\/ACC-General-Event-Release-_2_V1_2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/","og_locale":"en_US","og_type":"article","og_title":"Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25 - Pharma Trend","og_description":"Cleerly to Present Late-Breaking Findings and Participate in Key ACC.25 Sessions DENVER–(BUSINESS WIRE)–#AI—Cleerly, the leader in cardiovascular AI imaging, announces its participation in the American College of Cardiology Annual Scientific Session + Expo (ACC.25) from March 29-31, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Cleerly will share its late-breaking findings on Artificial ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/","og_site_name":"Pharma Trend","article_published_time":"2025-03-27T18:02:50+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250327234965\/en\/2421585\/22\/ACC-General-Event-Release-_2_V1_2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25","datePublished":"2025-03-27T18:02:50+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/"},"wordCount":553,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250327234965\/en\/2421585\/22\/ACC-General-Event-Release-_2_V1_2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/","url":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/","name":"Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250327234965\/en\/2421585\/22\/ACC-General-Event-Release-_2_V1_2.jpg","datePublished":"2025-03-27T18:02:50+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250327234965\/en\/2421585\/22\/ACC-General-Event-Release-_2_V1_2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250327234965\/en\/2421585\/22\/ACC-General-Event-Release-_2_V1_2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-late-breaking-clinical-trial-results-on-cardiovascular-risk-in-women-at-acc-25\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60996"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60996\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}